Synthesis and structure-activity relationships of 2-amino-1- aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 8163-8167

  Reddy, Gadarla Randheer ^a   Kuo, Ching Chuan ^a   Tan, Uan Kang ^b   Coumar, Mohane Selvaraj ^a   Chang, Chi Yen ^a   Chiang, Yi Kun ^a   Lai, Mei Jung ^d   Yeh, Jiann Yih ^a   Wu, Su Ying ^a   Chang, Jang Yang ^a,c   Liou, Jing Ping ^d   Hsieh, Hsing Pang ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TECHNOLOGY AND SCIENCE INSTITUTE OF NORTHERN TAIWAN   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 METHOXY 1 (3',4',5' TRIMETHOXYBENZOYL)NAPHTHALENE; 2 HYDROXY 6 METHOXY 1 (3',4',5' TRIMETHOXYBENZOYL)NAPHTHALENE; COLCHICINE; ETOPOSIDE; NAPHTHALENE DERIVATIVE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

ANISOLES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; NAPHTHALENES; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 58149096782     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8008635     Document Type: Article

References (33)

1. (a) Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a Target for Anticancer Drugs: Agents Which Interact with the Mitotic Spindle. Med. Res. Rev. 1998, 18, 259-296.
2. (b) Jordan, M. A.; Wilson, L. Microtubules as a Target for Anticancer Drugs. Nat. Rev. Cancer 2004, 4, 253-265.
3. (a) Tozer, G. M.; Akerman, S.; Cross, N. A.; Barber, P. R.; Björndahl, M. A.; Greco, O.; Harris, S.; Hill, S. A.; Honess, D. J.; Ireson, C. R.; Pettyjohn, K. L.; Prise, V. E.; Reyes-Aldasoro, C. C.; Ruhrberg, C; Shima, D. T.; Kanthou, C. Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors. Cancer Res. 2008, 68, 2301-2311.
4. (b) Hinnen, P. Eskens, FALM Vascular Disrupting Agents in Clinical Development. Br. J. Cancer 2007, 96, 1159-1165.
5. (c) Siemann, D. W., Ed. Vascular-Targeted Therapies in Oncology; John Wiley & Sons: Chichester, U.K., 2006.
6. (d) Siemann, D. W.; Bibby, M. C.; Dark, G. G.; Dicker, A. P.; Eskens, F. A. L. M.; Horsman, M. R.; Marme, D.; LoRusso, P. M. Differentiation and Definition of Vascular-Targeted Therapies. Clin. Cancer Res. 2005, 11, 416-420.
7. (e) Gaya, A. M.; Rustin, G. J. Vascular Disrupting Agents: A New Class of Drug in Cancer Therapy. Clin. Oncol. 2005, 17, 277-290.
8. (f) Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting Tumour Blood Vessels. Nat. Rev. Cancer 2005, 5, 423-435.
9. (g) Patterson, D. M.; Rustin, G. J. S. Vascular Damaging Agents. Clin. Oncol. 2007, 19, 443-456.
10. (a) Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal Chemistry of Combretastatin A4: Present and Future Directions. J. Med. Chem. 2006, 49, 3033-3044.
11. (b) Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical Design of Antimitotic Agents Based on Combretastatins. Curr. Pharm. Des. 2005, 11, 1655-1677.
12. (c) Li, Q.; Sham, H. L. Discovery and Development of Antimitotic Agents That Inhibit Tubulin Polymerisation for the Treatment of Cancer. Expert Opin. Ther. Pat. 2002, 12, 1663-1702.
13. (d) Mahindroo, N; Liou, J. P.; Chang, J. Y.; Hsieh, H. P. Antitubulin Agents for the Treatment of Cancer. A Medicinal Chemistry Update. Expert. Opin. Ther. Pat. 2006, 16, 647-691.
14. (e) Chaplin, D. J.; Horsman, M. R.; Siemann, D. W. Current Development Status of Small-Molecule Vascular Disrupting Agents. Curr. Opin. Invest. Drugs 2006, 7, 522-528.
15. (f) Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Cara, C. L.; Preti, D.; Fruttarolo, F.; Pavani, M. G.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Cristina, A. D.; Balzarini, J.; Hadfield, J. A.; Brancale, A.; Hamel, E. Synthesis and Biological Evaluation of 2- and 3-Aminobenzo[b]thiophene Derivatives as Antimitotic Agents and Inhibitors of Tubulin Polymerization. J. Med. Chem. 2007, 50, 2273-2277.
16. Liou, J. P.; Chang, C. W.; Song, J. S.; Yeh, C. F.; Hung, H. H.; Liu, S. H.; Hsieh, H. P. Synthesis and Structure-Activity Relationship of 2-Aminobenzophenone Derivatives as Antimitotic Agents. J. Med. Chem. 2002, 45, 2556-2562.
17. Romagnoli, R.; Baraldi, P. G.; Pavani, M. G.; Tabrizi, M. A.; Preti, D.; Fruttarolo, F.; Piccagli, L.; Jung, M. K.; Hamel, E.; Borgatti, M.; Gambari, R. Synthesis and Biological Evaluation of 2-Amino-3-(3′,4′,5′- trimethoxybenzoyl)-5-aryl thiophenes as a New Class of Potent Antitubulin agents. J. Med. Chem. 2006, 49, 3906 3915.
18. Romagnoli, R.; Baraldi, P. G.; Remusat, V.; Carrion, M. D.; Lopez Cara, C.; Preti, D.; Fruttarolo, F.; Pavani, M. G.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Balzarini, J.; Jordan, M. A.; Hamel, E. Synthesis and Biological Evaluation of 2-(3′,4′,5′-Trimethoxybenzoyl)-3-amino 5-aryl Thiophenes as a New Class of Tubulin Inhibitors. J. Med. Chem. 2006, 49, 6425-6428.
19. Chang, J. Y.; Yang, M. F.; Chang, C. Y.; Chen, C. M.; Kuo, C. C.; Liou, J. P. 2-Amino and 2′-Aminocombretastatin Derivatives as Potent Antimitotic Agents. J. Med. Chem. 2006, 49, 6412-6415.
20. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Cara, C. L.; Preti, D.; Fruttarolo, F.; Pavani, M. G.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Cristina, A. D.; Balzarini, J.; Hadfield, J. A.; Brancale, A.; Hamel, E. Synthesis and Biological Evaluation of 2- and 3-Aminobenzo[b-]thiophene Derivatives as Antimitotic Agents and Inhibitors of Tubulin Polymerization. J. Med. Chem. 2007, 50, 2273-2277.
21. Romagnoli, R.; Baraldi, P. G.; Sarkar, T.; Carrion, M. D.; Cara, C. L.; Cruz-Lopez, O.; Preti, D.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Cristina, A. D.; Zonta, N.; Balzarini, J.; Brancale, A.; Hsieh, H. P.; Hamel, E. Synthesis and Biological Evaluation of 1-Methyl-2-(3′,4′,5′- trimethoxybenzoyl)-3-aminoindoles as a New Class of Antimitotic Agents and Tubulin Inhibitors. J. Med. Chem. 2008, 51, 1464-1468.
22. (a) Liou, J. P.; Chang, Y. L.; Kuo, F. M.; Chang, C. W.; Tseng, H. Y.; Wang, C. C.; Yang, Y. N.; Chang, J. Y.; Lee, S. J.; Hsieh, H. P. Concise Synthesis and Structure-Activity Relationships of Combretastatin A-4 Analogues, 1-Aroylindoles and 3-Aroylindoles, as Novel Classes of Potent Antitubulin Agents. J. Med. Chem. 2004, 47, 4247-4257.
23. (b) Liou, J. P.; Mahindroo, N.; Chang, C. W.; Guo, F. M.; Lee, S. W. H.; Yeh, T. K.; Tan, U. K.; Kuo, C. C.; Chang, Y. W.; Lu, P. H.; Tung, Y. S.; Chang, J. Y.; Hsieh, H. P. Structure-Activity Relationship Studies of 3-Aroylindoles as Potent Antimitotic Agents. ChemMedChem 2006, 1, 1106-1118.
24. McDermed, J. D.; McKenzie, G. M.; Philips, A. P. Synthesis and Pharmacology of Some 2-Aminotetralines Dopamine Receptor Agonists. J. Med. Chem. 1975, 18, 362-367.
25. Worbel, J.; Millen, J; Sredy, J.; Dietrich, A.; Gorham, B. J.; Malamas, M.; Kelly, J. M.; Bauman, J. G.; Harrison, M. C.; Jones, L. R.; Guinosso, C.; Sestanj, K. Synthesis of Tolrestat Analogoues Containing Additional Substituents in the Ring and Their Evalution as Aldose Reductase Inhibitors. Identification of Potent Orally Active 2-Fluoro Derivatives. J. Med. Chem. 1991, 34, 2504-2520.
26. Hendrickson, J. B.; Bengeron, R. Triflamides: New Acylating and Triflating Reagents. Tetrahedron. Lett. 1973, 46, 4607-4610.
27. Martinez, A. G.; Alvarez, R. M.; Aguirre, J. A.; Subramanian, L. R. Mechanism of Hydrogenolysis. Part 1. Catalytic Hydrogenation of Vinyl and Aryltrifluoromethanesulphonates. J. Chem. Soc., Perkin Trans. 1 1986, 1595-1598.
28. Frustner, A.; Leitner, A.; Mendez, M.; Krause, H. Iron Catalyzed Cross Coupling Reactions. J. Am. Chem. Soc. 2002, 124, 13856-13863.
29. Wolfe, J. P.; Ahman, J.; Sadighi, J. P.; Singer, R. A.; Buchwald, S. L. An Ammonia Equivalent for the Palladium-Catalyzed Ammination of Arylhalides and Triflates. Tetrahedron Lett. 1997, 36, 6367-6370.
30. Dax, C.; Coincüon, M.; Sygusch, J.; Blonski, C. Hydroxynaphthaldehyde Phosphate Derivatives as Potent Covalent Schiff Base Inhibitors of Fructose-1,6-bisphosphate Aldolase. Biochemistry 2005, 44, 5430-5443.
31. Chang, J. Y.; Hsieh, H. P.; Chang, C. Y.; Hsu, K. S.; Chiang, Y. F.; Chen, C. M.; Kuo, C. C.; Liou, J. P. 7-Aroyl-aminoindoline-1-sulfonamides as a Novel Class of Potent Antitubulin Agents. J. Med. Chem. 2006, 49, 6656-6659.
32. Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee, S. J.; Chang, Y. L.; Chen, L. T.; Chang, J. Y. BPR0L075, a Novel Synthetic Indole Compound with Antitumoral Activity in Vivo. Cancer Res. 2004, 64, 4621-4628.
33. Liou, J. P.; Hsu, K. S.; Kuo, C. C.; Chang, C. Y.; Chang, J. Y. A Novel Oral Indoline-Sulfonamide Agent, J30, Exhibits Potent Activity against Human Cancer cells in Vitro and in Vivo through the Disruption of Microtubule. J. Pharmacol. Exp. Ther. 2007, 323, 398-405.